In 2016, the global pharmaceutical market size reached more than 1 trillion US dollars. In spite of the rise of pharmaceutical research & development cost and the decline of approval number of small molecular drugs, the research and development of anti-tumor drugs and orphan drugs remained robust last year. On the other hand, with the coming patent cliff of biological products, biosimilars were emerging. In this paper, we select some of the blockbusters in 2016, covering the frontiers of drug development for anti-infection, antitumor, central nervous system and other areas, and provide a review of 2016 domestic hotspots in pharmaceutical industry.

drug development  /  anti-infection drug  /  anti-tumor drug  /  central nervous system drug  /  biosimilar  /  frontiers in drug development